Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin

Gómez-Millán, Jaime; Toledo, M. D.; Lupianez, Y.; Rueda, Antonio; Trigo, José; Sachetti, Antonio; Medina, J. A.

doi:10.1007/s12094-012-0925-9

Cited by 13 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Disappointing long-term results of concomitant CRT deserve further evaluation and investigation since severe late toxicity following CRT is common in long-term survivors and a higher mortality from causes other than disease progression is reported in treated patients [43,46]. The development of more potent IC regimens may further improve patient outcomes.…”

Section: Larynx Preservationmentioning

confidence: 99%

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Denaro¹,

Russi

Adamo

et al. 2014

Oncology

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer death worldwide. Its treatment is complex and evolving. In general, early-stage disease may be managed with single-modality treatment while an advanced stage (about 60% of clinical presentation) needs a multidisciplinary approach. In this setting concurrent chemoradiation has been associated with improvement in locoregional control and organ preservation, but at the cost of significant acute and chronic toxicity. Molecular target therapies specially directed to epidermal growth factor receptor (EGFR) might improve the outcomes and reduce toxicities. In recurrent-metastatic (R/M) HNSCC, cetuximab, a monoclonal antibody against EGFR, plus platinum-based chemotherapy (CT) allow an overall survival (OS) of about 10 months. However, the prognosis for R/M-HNSCC remains dismal and additional efforts are needed. At the 2013 American Society of Clinical Oncology (ASCO) Meeting, data on induction CT, anti-EGFR inhibitors, innovative molecular targets and predictor factors were reported. Further results on target therapies were presented at the European Cancer Congress (ECC) 2013, where a large study also showed that hyperfractionated radiotherapy (RT) improve OS rates compared with standard RT. The aim of this review is to discuss current standards and emerging therapies by considering recent new updates.

show abstract

Section: Larynx Preservationmentioning

confidence: 99%

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Denaro¹,

Russi

Adamo

et al. 2014

Oncology

View full text Add to dashboard Cite

show abstract

“…Various studies with long term tumour control and survival as end points have identified such cut-off values for PTV ranging from 19.6 cm 3 to 35 cm 3 and for TTV, from 22.8 cm 3 to 110 cm 3 depending upon the places where these were conducted. [13][14][15][16][17][18][19][20][21][22][23] In our study, for early response evaluation at 3 months of CCRT "optimal threshold cut-off" for PTV and TTV were higher (41 cm 3 and 42 cm 3 , respectively), primarily owing to a large tumour burden in our country. This method may categorise patients into either a favourable group (TV less than cut-off) or unfavourable group (TV more than cut-off) at a pre-treatment stage.…”

Section: Discussionmentioning

confidence: 65%

Tumour volumes: Predictors of early treatment response in locally advanced head and neck cancers treated with definitive chemoradiation

Ahlawat

Rawat

Kakria

et al. 2016

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

“…Impact of primary tumor volume on prognosis and prognostic "threshold cut-off" of primary tumor volume -all head and neck sites Locally advanced head and neck cancers have a poor prognosis. [24][25][26] With the rapid advancement in the delivery of RT and the rapidly emerging era of organ preservation, CCRT is well-established treatment modality in locally advanced head and neck cancers. It is important to determine the predictors for outcome in these patients who are to be treated with CCRT.…”

Section: Variability Of Tumor Volume Within Same T-staged Tumorsmentioning

confidence: 99%

Utilization and incorporation of tumor volume data in staging and prognostication of head and neck squamous cell carcinoma treated with definitive radiotherapy: A systematic review

Ahlawat

Rawat

Kakria

et al. 2015

Asian Journal of Oncology

View full text Add to dashboard Cite

Head and neck squamous cell cancers (HNSCC) are a group of heterogeneous tumors, evident by their diverse behavior and natural history. The largest diameter of tumor measured for T classification may not necessarily reflect the true tumor dimension. There is a need to take into account certain other feature(s) of these tumors other than the maximum single dimension which can reflect the true tumor burden more accurately. Tumor volume has been shown to be a useful and accurate tool burden because it is a measurement of tumor burden in all three dimensions. This review article has compiled and reviewed the literature published in past on impact of tumor volumes (TVs) on the prognosis of head and neck cancers. A comprehensive literature search was performed in PubMed for terms “clonogens,” “TV” or “primary TV (PTV)” or “nodal volume” or “total TV (TTV)” or “volumetric analysis of TV in head and neck” or “predicting response in head and neck cancer” “prognostic factors head and neck cancers” and “outcome in head and neck cancer.” We identified 33 studies which have commented on the impact of TV in HNSCC on treatment outcome, 9 of these had analyzed PTV, 11 studies had analyzed total nodal volume, and 14 studies have analyzed TTV. Besides these, we have dealt with laryngeal cancers separately with 9 studies. This review article is also aimed to enhance our knowledge further regarding how best a physician can incorporate TV data in staging and predicting response to radiotherapy.

show abstract

Competing causes of death in patients with locoregionally advanced head and neck cancer treated with concomitant boost radiation plus concurrent weekly cisplatin

Abstract: Patients with locoregionally advanced head and neck cancer treated with concomitant boost accelerated radiation plus chemotherapy show significant risks of mortality from causes other than disease progression.

Cited by 13 publications

References 21 publications

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Tumour volumes: Predictors of early treatment response in locally advanced head and neck cancers treated with definitive chemoradiation

Utilization and incorporation of tumor volume data in staging and prognostication of head and neck squamous cell carcinoma treated with definitive radiotherapy: A systematic review

Contact Info

Product

Resources

About